SummaryRMgm-667
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption, Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 21958024 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
Other information parent line | P.berghei ANKA 507cl1 (RMgm-7) is a reference ANKA mutant line which expresses GFP under control of a constitutive promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 16242190). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Talman A.M.; Sinden R.E. |
Name Group/Department | Department of Life Sciences |
Name Institute | Imperial College |
City | London |
Country | UK |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-667 |
Principal name | GESTKO-GFP |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Gametocyte production was comparable to wild type parasites. Strongly reduced fertilisation. Evidence is presented that egress of both males and female gametes from the erythrocyte is affected |
Fertilization and ookinete | Strongly reduced fertilisation and production of ookinetes. Evidence is presented that egress of both males and female gametes from the erythrocyte is affected |
Oocyst | Strongly reduced oocyst formation (94-98%) |
Sporozoite | The low numbers of oocysts produce normal numbers of sporozoites that are able to invade salivary glands. Sporozoites showed normal gliding motility and cell invasion capacity. Infectivity of sporozoites is reduced (see 'Additional remarks phenotype). |
Liver stage | The low numbers of oocysts produce normal numbers of sporozoites that are able to invade salivary glands. Sporozoites showed normal gliding motility and cell invasion capacity. Infectivity of sporozoites is reduced (see 'Additional remarks phenotype'). |
Additional remarks phenotype | Mutant/mutation Phenotype The low numbers of oocysts produce normal numbers of sporozoites that are able to invade salivary glands. Infectivity of sporozoites to mice is normal after intravenous injection of sporozoites; however, sporozoite infectivity after subcutaneous injection is reduced. Sporozoites showed normal gliding motility and hepatocyte invasion capacity. Evidence is presented for a reduced cell traversal/wounding of mutant sporozoites. Additional information Evidence has been presented for a location of GEST in osmiophilic bodies (OB) of male and female gametocytes through analysis of a transgenic mutant expressing GFP-tagged GEST (see mutant RMgm-668). In addition evidence was found for secretion of GEST from OBs upon activation of gametocytes. Evidence has been presented for secretion of GEST by sporozoites through analysis of a transgenic mutant expressing GFP-tagged GEST (see mutant RMgm-668). Partial rescue of the phenotype was obtained in complementation studies in which mutant parasites were complemented with either the complete P. berghei gest gene or the P. falciparum gest gene. Those genes were introduced in the mutant by transfection of episomal constructs that contained the hdhfr selectable marker. Complemented mutants were selected with the drug WR99210. Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1312700 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1449000 | ||||||||||||||||||||||||
Gene product | gamete egress and sporozoite traversal protein, putative | ||||||||||||||||||||||||
Gene product: Alternative name | GEST, gamete egress and sporozoite traversal protein | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | SacII, KpnI, HpaI | ||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The GESTKO plasmid was generated by amplifying 450 and 520 bp of the 5' and 3' UTR of the GEST coding sequence (PBANKA_131270) respectively, with primers 1 and 2 and 3 and 4 respectively. These fragments were inserted into pOB90 (courtesy of O. Billker) on either side of the Toxoplasma gondi dhfr gene, conferring resistance to pyremethamine. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | GFP (gfp-mu3) | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | Plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence |
" 1 aattcactgg ccgtcgtttt acaacgtcgt gactgggaaa accctggcgt
| ||||||||||||||||||
Restriction sites to linearize plasmid | KspI (SacII) | ||||||||||||||||||
Selectable marker used to select the mutant parasite | gfp (FACS) | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | FACS (flowsorting) | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | The GFP gene (1 copy) has been inserted into the 230p locus (PBANKA_030600) by double cross-over integration. | ||||||||||||||||||
Additional remarks selection procedure | This reporter mutant expressing GFP does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence. | ||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1133300 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1357100 | ||||||||||||||||||
Gene product | elongation factor 1-alpha | ||||||||||||||||||
Gene product: Alternative name | eef1a | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | 230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |